Ashwini A. Katre

Geneve, GE, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 158 publications

Utilization of a 3-D tissue engineered model to investigate the effects of perfusion on gynecologic cancer biology.

Utilization of a 3-D tissue engineered model to investigate the effects of perfusion on gynecologic cancer biology.

Journal: Journal of tissue engineering

Published: July 20, 2021

Sequential modulation of the Wnt/β-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance.

Sequential modulation of the Wnt/β-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance.

Journal: Gynecologic oncology

Published: July 13, 2021

Understanding the effect of mechanical forces on ovarian cancer progression.

Understanding the effect of mechanical forces on ovarian cancer progression.

Journal: Gynecologic oncology

Published: December 08, 2020

Corrigendum to 'Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer' [Gynecologic Oncology 157 (2020) 765-774].

Corrigendum to 'Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer' [Gynecologic Oncology 157 (2020) 765-774].

Journal: Gynecologic oncology

Published: August 26, 2020

Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.

Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.

Journal: Gynecologic oncology

Published: August 14, 2020

Neutralization of TGFβ Improves Tumor Immunity and Reduces Tumor Progression in Ovarian Carcinoma.

Neutralization of TGFβ Improves Tumor Immunity and Reduces Tumor Progression in Ovarian Carcinoma.

Journal: Molecular cancer therapeutics

Published: May 15, 2020

Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer.

Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer.

Journal: Cancer medicine

Published: March 10, 2020

Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor Microenvironment.

Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor Microenvironment.

Journal: Cancers

Published: March 02, 2020

Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.

Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.

Journal: Gynecologic oncology

Published: December 09, 2019

Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer.

Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer.

Journal: Therapeutic advances in medical oncology

Published: August 30, 2019

Large, Non-Cavity Distorting Intramural Leiomyomas Decrease Leukemia Inhibitory Factor in the Secretory Phase Endometrium.

Large, Non-Cavity Distorting Intramural Leiomyomas Decrease Leukemia Inhibitory Factor in the Secretory Phase Endometrium.

Journal: Reproductive sciences (Thousand Oaks, Calif.)

Published: February 19, 2019

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Journal: Oncotarget

Published: May 04, 2018

Showing 1-12 of 158

Last Updated: 09/26/2026